Medical devices, healthcare technology and the business of care
PMA approval · P160055

LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)

Rxsight, Inc. · Decision date Nov 22, 2017

FDA DECISIONP160055

What did the FDA approve?

FDA records P160055 as an original PMA application. The recorded decision is approval, dated Nov 22, 2017.

FDA approval order statement

Approval for The Light Adjustable Lens and Light Delivery Device system is indicated for the reduction residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag, in adult patients: 1) With pre-existing corneal astigmatism of => 0.75 diopters; and 2) Without pre-existing macular disease. The system also reduces the likelihood of clinically significant residual spherical refractive errors.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Nov 22, 2017

FDA source record

Regulatory record facts

Identifier
P160055
Regulatory pathway
Premarket approval application
Applicant
Rxsight, Inc.
Product code
PZK
Decision code
APPR
Decision date
Nov 22, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Light adjustable lens (LAL) and light delivery device (LDD).

Applicant
Rxsight, Inc.
Product code
PZK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160055 received

    Application receipt date recorded by FDA.

  2. P160055 · FDA decision

    APPR

  3. P160055/S056 · Related supplement

    RxSight Light Adjustable Lens and Light Delivery Device

  4. P160055/S058 · Related supplement

    RxSight Light Adjustable Lens and Light Delivery Device

  5. P160055/S057 · Related supplement

    RxSight Light Adjustable Lens and Light Delivery Device

Timeline entries are records held by MedtechLedger for P160055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160055

Product / regulatory recordCompanyPathwayDecision dateSource
Rxsight, Inc.PMA supplementSep 3, 2026FDA
Rxsight, Inc.PMA supplementOct 22, 2026FDA
Rxsight, Inc.PMA supplementNov 5, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Rxsight, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Columbia, Aliso Viejo, CA, 92656

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records